Randomized, Open-label, Multi-center and Phase 3 Clinical Trial to Compare the Efficacy and Safety of 'INNOCELL Immuncell-LC Group' and 'Non-treatment Group' in Patient Undergone Curative Resection (PEIT, RFA or Operation) for Hepatocellular Carcinoma in Korea.

Trial Profile

Randomized, Open-label, Multi-center and Phase 3 Clinical Trial to Compare the Efficacy and Safety of 'INNOCELL Immuncell-LC Group' and 'Non-treatment Group' in Patient Undergone Curative Resection (PEIT, RFA or Operation) for Hepatocellular Carcinoma in Korea.

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Sep 2015

At a glance

  • Drugs T-lymphocyte cell therapy (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Sponsors Green Cross Cell
  • Most Recent Events

    • 23 Sep 2015 Protocol has been amended to change in primary endpoint and treatment arms, as per ClinicalTrials.gov record.
    • 13 Aug 2013 Final results of the trial will be available soon, according to the media release.
    • 13 Aug 2013 Mid-tern analysis results presented at the 4th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE), according to an Innocell media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top